Skip to content

Updates: Products

aProximate™ Assay-Ready Plates launch poster.
18th January, 2023

New Product Launched – aProximate™ 96-well Assay-Ready Plates

Get our aProximate™ PTCs to your lab anywhere in the world (24 & 96-well plates) aProximate™ Assay-ready plates contain freshly isolated primary human proximal tubule cells (PTCs). The plates are…

Read update
Glomerulus
11th August, 2022

How a glomerulus in vitro model can accelerate drug development

The glomerulus is the part of the kidney involved in the filtration of solutes and waste from the blood. Damage to the glomerulus by diabetes mellitus, hypertension, glomerulonephritis, or…

Read update
24 Plate Product
13th July, 2022

New Product Launched – aProximate™ Assay-Ready Plates for transporter studies

aProximate™ Assay-ready plates contain freshly isolated primary human proximal tubule cells (PTCs). The plates are provided in an easy to use 24-well Transwell® format. Visit our product page…

Read update
Retinal organoids
28th April, 2022

Retinal Organoids for Drug Discovery

Retinal diseases have been at the forefront of gene and cell therapy over the last 30 years with conditions such as macular degeneration and Stargardt disease likely to be…

Read update
Newcells Biotech
5th November, 2021

iPSC-derived Retinal Organoids: an alternative in vitro model for drug discovery

What retinal models are available for drug development? Animal models are the most frequently used for investigating safety and efficacy of ophthalmic drugs. However, due to several key physiological differences,…

Read update
Global scientific expertise built into every Newcells Biotech product and service
25th May, 2021

Global scientific expertise built into every NB product & service

At Newcells Biotech, we build our Industry leading scientific expertise and technical excellence into all the products and services we offer to our customers, delivering innovative solutions for drug…

Read update
1st August, 2024

Press Release: Newcells Biotech launches high-content and high-throughput imaging suite to advance pre-clinical drug development programmes

Newcells Biotech (“Newcells”), a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes,…

Read update
Rhys and collin at JSOT 2024
12th July, 2024

The Intensity of Innovation: Insights from the Japanese Society of Toxicology Conference

A Unique Exhibition-Poster Integration One striking feature of JSOT is how they seamlessly integrate exhibitions with poster sessions. Exhibitors and poster presenters are…

Read update
8th July, 2024

Press Release: Newcells Biotech appoints Emile Shaffu as Director of Sales

Newcells Biotech (“Newcells”), a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes,…

Read update
28th June, 2024

Newsletter June 2024

How does Newcells works with their clients? Listen to our CEO, Dr Mike Nicholds explaining. Webinar on demand: Moving compounds to IND using predictive retinal models. Our panel of experts…

Read update
11th June, 2024

Press Release : Newcells Biotech strengthens executive and US team with key appointments

Dr Valeria Chichagova appointed as Director of Technology, Dr Colin Brown as Chief Scientific Officer, and Professor Lyle Armstrong as Scientific Advisor New US commercial appointments also announced…

Read update
6th March, 2024

Biotech firm raises £2.3m for lab models that help avoid animal testing

The Newcastle-based company has secured funding from existing investors including the North East Venture Fund, supported by the European Regional Development Fund and managed by Mercia Ventures, Mercia’s own funds…

Read update

Get our latest updates straight to your inbox